Tumor News and Research

RSS

Discovery of genetic pattern that may predict response to Gleevec in GIST

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec).

22 Apr 2009

Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers

Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo.

22 Apr 2009

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.

22 Apr 2009

Light-scattering techniques may help determine chemo's effectiveness

By examining the patterns in which light bounces off cell surfaces, researchers may be able to assess chemotherapy's success in inducing cancer cell death, according to a study led by investigators in the Duke Comprehensive Cancer Center and Duke's Pratt School of Engineering.

22 Apr 2009

$Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma$

Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma

Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to researchers from the Kimmel Cancer Center at Jefferson.

22 Apr 2009

New drug to target tumor cells and blood vessels

Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

21 Apr 2009

Experimental agent shows promise for advanced biliary cancer

An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.

21 Apr 2009

Survey identifies factors associated with early detection of melanoma in older men

Older men whose melanoma is detected by a physician are more likely to have thinner and therefore more treatable tumors at diagnosis, according to results of a survey published in the April issue of Archives of Dermatology.

21 Apr 2009

New drug to target tumor cells and blood vessels

21 Apr 2009

Pancreatic cancer cells targeted with combo therapy

A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report.

21 Apr 2009

Pregnancy hormone hCG protects against breast cancer even in short-term treatments

One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.

21 Apr 2009

New insights into protein p75's role Alzheimer's disease

New research at the Salk Institute for Biological Studies casts the role of a neuronal growth factor receptor - long suspected to facilitate the toxic effects of beta amyloid in Alzheimer's disease - in a new light, suggesting the molecule actually protects the neuron in the periphery from beta amyloid-induced damage.

21 Apr 2009

Human lung tumors can eliminate Vitamin D

Human lung tumors have the ability to eliminate Vitamin D, a hormone with anti-cancer activity, a new study from the University of Pittsburgh Cancer Institute (UPCI) suggests.

20 Apr 2009

Overexpression of PEA-15 protein shrinks breast cancer tumors

Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.

20 Apr 2009

Grapefruit juice boosts efficacy of drug rapamycin

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given.

20 Apr 2009

Genetic source of rare cancer pleuropulmonary blastoma discovered

The search for the cause of an inherited form of a rare, aggressive childhood lung cancer has uncovered important information about how the cancer develops and potentially sheds light on the development of other cancers.

20 Apr 2009

Fulvestrant influences the effects of chemotherapy drugs on breast cancer cells

Researchers from The Cancer Institute of New Jersey (CINJ) are converging on Denver for the 100th Annual Meeting of the American Association for Cancer Research (AACR) to share their findings on a combined treatment targeting breast cancer that is stimulated by the hormone estrogen (estrogen receptive positive).

20 Apr 2009

First noninvasive technique to accurately predict mutations in human brain tumors

Donald O'Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine and colleagues, were able to accurately predict the specific genetic mutation that caused brain cancer in a group of patients studied using magnetic resonance imaging (MRI).

20 Apr 2009

Nanoparticle delivery of a fully functioning copy of P53 tumor suppressor gene

Dr. Esther Chang describes the most recent developments in human trials of the first systemic, non-viral, tumor-targeted, nanoparticle method designed to restore normal gene function to tumor cells while completely bypassing normal tissue April 21 at an American Association of Anatomists (AAA) scientific session at Experimental Biology 2009 in New Orleans.

20 Apr 2009

Chemopreventive isothiocyanates selectively depletes mutant p53 in tumor cells

Researchers at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center have demonstrated that naturally-occurring compounds can selectively deplete mutant p53 and restore "wild type" function to p53 in a variety of tumor cells.

20 Apr 2009